[Neoadjuvant combined therapy in stage IIIA if non-small-cell bronchial cancer].

Abstract

BACKGROUND AND OBJECTIVE The overall prognosis of patients with stage IIIA non-small-cell lung cancer is unfavourable (median survival time 12 months). Tolerance to and efficacity of a multimodal neoadjuvant treatment was assessed in a prospective study. PATIENTS AND METHODS 25 patients (median age 59 [37-69] years), with histologically confirmed… (More)

Topics

Cite this paper

@article{Thomas1997NeoadjuvantCT, title={[Neoadjuvant combined therapy in stage IIIA if non-small-cell bronchial cancer].}, author={M. Thomas and Christian Ruebe and Michael Semik and Kerstin Junker and Michael von Eiff}, journal={Deutsche medizinische Wochenschrift}, year={1997}, volume={122 33}, pages={993-8} }